LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Hutchison China MediTech Ltd ADR

Lezárt

SzektorEgészségügy

15.29 1.12

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

15.12

Maximum

15.38

Fő mutatók

By Trading Economics

Bevétel

-6.9M

6M

Értékesítés

9.4M

162M

P/E

Szektor átlag

68

51.198

Profit margin

3.676

Munkavállalók

1,811

EBITDA

5.6M

-5M

Ajánlások

By TipRanks

Ajánlások

Vétel

12 hónapos előrejelzés

+36.63% upside

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

-302M

2.4B

Előző nyitás

14.17

Előző zárás

15.29

Technikai pontszám

By Trading Central

Bizalom

Strong Bearish Evidence

Hutchison China MediTech Ltd ADR Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2025. jún. 6. 14:31 UTC

Eredményjelentés

New York State Retirement Fund Posts 5.84% Annual Investment Return

2025. jún. 6. 20:50 UTC

Piaci beszéd

Basic Materials Roundup: Market Talk

2025. jún. 6. 20:50 UTC

Piaci beszéd

Auto & Transport Roundup: Market Talk

2025. jún. 6. 20:33 UTC

Eredményjelentés

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

2025. jún. 6. 19:36 UTC

Piaci beszéd

Oil Futures Post Solid Weekly Gains -- Market Talk

2025. jún. 6. 19:28 UTC

Piaci beszéd

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

2025. jún. 6. 18:46 UTC

Piaci beszéd

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

2025. jún. 6. 18:02 UTC

Piaci beszéd

U.S. Oil Rig Count Continues to Decline -- Market Talk

2025. jún. 6. 16:35 UTC

Eredményjelentés

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

2025. jún. 6. 16:34 UTC

Eredményjelentés

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

2025. jún. 6. 16:21 UTC

Piaci beszéd

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

2025. jún. 6. 16:20 UTC

Piaci beszéd

Auto & Transport Roundup: Market Talk

2025. jún. 6. 16:20 UTC

Piaci beszéd

Basic Materials Roundup: Market Talk

2025. jún. 6. 16:20 UTC

Piaci beszéd

Health Care Roundup: Market Talk

2025. jún. 6. 16:15 UTC

Piaci beszéd

Global Commodities Roundup: Market Talk

2025. jún. 6. 16:07 UTC

Piaci beszéd

Market Talk Roundup: Latest on U.S. Politics

2025. jún. 6. 16:07 UTC

Piaci beszéd

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

2025. jún. 6. 15:53 UTC

Piaci beszéd

Mexican Inflation Seen Rising in May -- Market Talk

2025. jún. 6. 15:36 UTC

Piaci beszéd

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

2025. jún. 6. 15:36 UTC

Piaci beszéd

Global Forex and Fixed Income Roundup: Market Talk

2025. jún. 6. 15:33 UTC

Piaci beszéd

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

2025. jún. 6. 15:16 UTC

Piaci beszéd

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

2025. jún. 6. 15:05 UTC

Piaci beszéd

Silver at its Highest In Nearly 15 Years -- Market Talk

2025. jún. 6. 14:35 UTC

Piaci beszéd

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

2025. jún. 6. 14:28 UTC

Piaci beszéd

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

2025. jún. 6. 14:28 UTC

Piaci beszéd

Global Forex and Fixed Income Roundup: Market Talk

2025. jún. 6. 14:28 UTC

Piaci beszéd

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

2025. jún. 6. 14:15 UTC

Piaci beszéd

Oil Rises on U.S.-China Talks Optimism -- Market Talk

2025. jún. 6. 14:12 UTC

Eredményjelentés

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

2025. jún. 6. 14:09 UTC

Eredményjelentés

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Társak összehasonlítása

Árváltozás

Hutchison China MediTech Ltd ADR Előrejelzés

Célár

By TipRanks

36.63% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 20.85 USD  36.63%

Magas 27 USD

Alacsony 14.7 USD

2 Wall Street elemző 12 hónapos célárain alapulva a(z)Hutchison China MediTech Ltd ADR termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Vétel

2 ratings

1

Vétel

1

Tartás

0

Eladás

Technikai pontszám

By Trading Central

14.24 / 14.78Támogatás & ellenállás

Rövid táv

Strong Bearish Evidence

Középtáv

Weak Bearish Evidence

Hosszú táv

Weak Bearish Evidence

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.